Study Shows High Adherence in People on CDK 4/6 Inhibitors
Since 2015, three cyclin-dependent kinase (CDK) 4/6 inhibitors have come onto the U.S. market as treatments for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or me...
CMS OKs Copay Accumulators For Drugs With No Generics
In a reverse course from its stance a year ago, CMS recently finalized a rule allowing nongrandfathered individual and group market plans to not count manufacturer copayment assistance toward members’ annual deduc...
Questions Surround Some DMD Drugs; More Near U.S. Market
Since 2016, the FDA has approved a handful of therapies to treat Duchenne muscular dystrophy (DMD). But some uncertainty exists over their effectiveness, in addition to concerns about their costs. Additional product...
Source: Pandemic Poses ‘Major Disruption’ to My Cancer Care
A longtime pharma industry expert spoke with AIS Health about their experience as someone with cancer during a pandemic. They asked to remain unidentified: AIS Health: What kind of cancer do you have, and when we...
New FDA Specialty approvals
✦ May 6: The FDA gave accelerated approval to Novartis Pharmaceuticals Corp.’s Tabrecta (capmatinib) for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesen...
News Briefs
✦ The Association for Accessible Medicines (AAM) filed an amicus brief May 13 in support of the Biologics Price Competition and Innovation Act of 2009 (BPCIA) remaining law if the Affordable Care Act (ACA) is inva...
Groups Call on CMS to Modify Medicare Home Infusion Benefit
As people are urged to stay home during the COVID-19 pandemic, CMS has been relaxing a series of health care service policies in support of this need. But one change it hasn’t made is to allow home infusion to be ...
Amid COVID-Spurred Shifts in Home Infusion, Model May Morph
With numerous hospitals focused on the COVID-19 pandemic and many areas under stay-at-home mandates, home infusion is more important than ever. Changes within the industry already have been seen, and the current sit...
Biosimilars May Be Impacting Payers’ Medical Benefit Spend
Over the past decade, commercial per-member per-month (PMPM) drug spend under the medical benefit has almost doubled, according to Magellan Rx Management, a division of Magellan Health, Inc. The company just rele...
Some Payers Say They May Allow Off-Label Use of Jelmyto
On April 15, the FDA approved the first drug for patients with low-grade upper tract urothelial cancer, UroGen Pharma Ltd.’s Jelmyto (mitomycin). It offers patients a nonsurgical option for a condition that often ...